Emory SOM Faculty | Memorial Sloan Kettering Gynecologic Oncology Fellow | Harvard OB-GYN | Views are my own
New York, USA
Joined March 2020
- Tweets250
- Following309
- Followers773
- Likes550
A privilege to provide commentary in @gynoncjnls on how we leverage the folate receptor to treat gynecologic malignancy. It’s time to outsmart cancer! @WinshipAtEmory
pubmed.ncbi.nlm.nih.gov/3966…
It’s standing room only at @WinshipAtEmory combined GYN onc and surg onc journal club as we refine our evidence-based #HIPEC protocol for #ovariancancer patients at Emory
@SusanModesitt @jscalici @s_illey @SethConcorsMD
Still beaming from the magic that was the @nycmarathon in the city I love so very much
🏃🏼♀️🏃🏼♀️🏃🏼♀️
My better half, Ryan Langdale of @TheChartisGroup, quoted in the @WSJ on consolidation in the cancer industry.
wsj.com/health/pharma/why-dr…
Excited to be named an early career new investigator by NRG oncology! Can’t wait to bring more of these #clinicaltrials to our patients at @WinshipAtEmory @EmoryGynOb
nrgoncology.org/Home/News/Po…
Our newest editorial is out now—bravo to #SENECA investigators for their collaborative effort. Excited to see what we can do with this database to improve our clinical care!
#Editorial on #SENECA study @SENECAStudy
@ bit.ly/3MA71Fm
#SLNmapping #EndometrialCancer
@Quique_ChC @ClinicaNavarra @JennyMueller @Doctor_Beryl
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @Frumovitz @HousseinELHAJJ3 @AinhoaMada @Jc_vilches @erodriguezglez @daggezmine @astraubhar
#WeeklyPodcast #LeadArticle #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc
Had a wonderful time joining @TuftsObGynRes on behalf of @EmoryGynOb to kick off this year’s Tufts OB/GYN grand rounds and talking about #fertility in #endometrialcancer
Antibody drug conjugates are an exciting new therapy, but so far targeting folate receptor + ovarian cancer is limited to high grade. Here, we show that low grade ovarian cancers have the same % of folate receptor positivity. Next up: see if these treatments benefit patients!
Wonderful new paper out from @Doctor_Beryl evaluating folate receptor alpha expression in low grade serous ovarian cancer. A biomarker-driven approach to treatment selection is promising. @TeamOvary_MSK @TeamEndo_MSK
pubmed.ncbi.nlm.nih.gov/3894…
Beryl Manning-Geist, MD retweeted
Newly arrived Winship gynecologic oncologist Beryl Manning-Geist, MD, kicks off the next session with a talk on targeted and hormone therapy options for treating low-grade epithelial ovarian cancer. #DDHO2024
Beryl Manning-Geist, MD retweeted
A wonderful gynecologic cancer session comes to a close with a panel discussion and patient case presentation with all of our speakers. #DDHO2024
Thrilled to participate in the editorial process, learn from the greats @David_Cohn_MD and work to bring forward advancements in GYN cancer care!
‼️ New editorial 📄 program initiative between @gynoncjnls and #BRIDGES 🌉 scholars 👏 @SGO_org @GYNCancer @GOG @David_Cohn_MD @Doctor_Beryl @MMAlHilli @sy_rachel @LAURAJMOULTON @DNasioudis
Podcast “debut” with @IJGConline on our work on ovarian preservation in patients with #endometrialcancer. Always a fun time with @pedroramirezMD and @JennyMueller_
What role does molecular subtyping play in guiding ovarian preservation in endometrial cancer❓❓Check this highly anticipated podcast by Dr. Mueller and @Doctor_Beryl @MSKCancerCenter #gyncsm #gyn
Thank you @IJGConline for featuring our study on caring for young patients with #endometrialcancer
@TeamEndo_MSK
#EditorsChoice Molecular and pathologic data to guide selection of patients with endometrioid #endometrialcancer for #ovarianpreservation
🖥️ bit.ly/3QLKFmV
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @Doctor_Beryl @RiosDoriaMD @leitaomd @aburustummd @TeamEndo_MSK
My “out of office” starting off a little differently than anticipated…
All is well and first vacation in a year begins NOW. Great flight crew support and medical kit @Delta!
Excellent read by the talented @tsialater!
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in #gynecologic malignancies
🔍 bit.ly/449nbxq
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4
Amazing experience learning from and working with @ClaireFriedma19 @DmitriyZamarin — so much to still discover about the immune system and GYN cancer! Read all about our study in @NatureMedicine
Check out our new story out in @NatureMedicine today: a phase II study of nivolumab in dMMR/hypermutated gynecologic cancers together with my dear friend @ClaireFriedma19 . link.springer.com/article/10… brief summary (thread):
Moving the needle on fertility preservation in #endometrialcancer : molecular data can refine our approach!
Exciting new paper from @Doctor_Beryl and @JennyMueller_ showing that integration of molecular and pathologic data can enhance selection of candidates with endometrial cancer for ovarian preservation. @TeamEndo_MSK @TeamOvary_MSK
pubmed.ncbi.nlm.nih.gov/3850…
Beryl Manning-Geist, MD retweeted
SGO Bridges - Impressive ground-breaking research career building initiative!
Green is the new black 🍀🍀
#2024SpecialIssue Indocyanine green and near infrared technology in the treatment of #GynCan
✳️ bit.ly/3T8ji71
@Doctor_Beryl @VanceBroach @leitaomd @AndreasObermair @zivanovicmd @aburustummd @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @OncoAlert @IJGCfellows @GynMe4
Hold for my upcoming #SGOBRIDGES phase II trial that moves raf/mek/fak inhibition + hormonal blockade to the FRONT-LINE in low grade serous #ovariancancer
Expected to start enrolling @MSKCancerCenter in the next few weeks 👍
We have made progress in low grade serous #OvarianCancer - but we need to start considering moving these trials to the frontline - Great point Dr. Moore! #SGOMtg #gyncsm
